{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+with+food",
    "query": {
      "intervention": "Capsule with food"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 495,
    "total_pages": 50,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+with+food&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-14T11:21:10.135Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04983940",
      "title": "Patient Satisfaction After Switching to Oral Testosterone Undecanoate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Testosterone Deficiency"
      ],
      "interventions": [
        {
          "name": "Jatenzo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 41,
      "start_date": "2021-06-18",
      "completion_date": "2023-04-06",
      "has_results": true,
      "last_update_posted_date": "2023-12-14",
      "last_synced_at": "2026-09-14T11:21:10.135Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04983940"
    },
    {
      "nct_id": "NCT04834778",
      "title": "A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Gastric Cancer",
        "Metastatic Breast Cancer",
        "Small-cell Lung Cancer",
        "Other Solid Tumors"
      ],
      "interventions": [
        {
          "name": "HC-5404-FU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HiberCell, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2021-06-08",
      "completion_date": "2024-01-30",
      "has_results": false,
      "last_update_posted_date": "2024-03-08",
      "last_synced_at": "2026-09-14T11:21:10.135Z",
      "location_count": 4,
      "location_summary": "Detroit, Michigan • Saint Paul, Minnesota • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04834778"
    },
    {
      "nct_id": "NCT05319912",
      "title": "A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ALXN1840 Enteric-coated Tablet",
          "type": "DRUG"
        },
        {
          "name": "ALXN1840 Non-coated Capsule",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 18,
      "start_date": "2014-04-07",
      "completion_date": "2014-05-29",
      "has_results": true,
      "last_update_posted_date": "2023-08-02",
      "last_synced_at": "2026-09-14T11:21:10.135Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05319912"
    },
    {
      "nct_id": "NCT00075803",
      "title": "Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma",
        "Infection",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Fluconazole",
          "type": "DRUG"
        },
        {
          "name": "Voriconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2003-11",
      "completion_date": "2007-09",
      "has_results": true,
      "last_update_posted_date": "2023-01-04",
      "last_synced_at": "2026-09-14T11:21:10.135Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Stanford, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00075803"
    },
    {
      "nct_id": "NCT04812366",
      "title": "Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Apalutamide 60mg Tab",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate 250mg",
          "type": "DRUG"
        },
        {
          "name": "Prednisone 5mg Tab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Niraparib 100mg Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Tazemetostat Pill",
          "type": "DRUG"
        },
        {
          "name": "Capivasertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of British Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 315,
      "start_date": "2021-09-21",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-09-14T11:21:10.135Z",
      "location_count": 5,
      "location_summary": "Sacramento, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04812366"
    },
    {
      "nct_id": "NCT04461587",
      "title": "Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coal Workers' Pneumoconiosis (Complicated)"
      ],
      "interventions": [
        {
          "name": "Pirfenidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pulmonary Research of Abingdon, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "40 Years to 79 Years"
      },
      "enrollment_count": 50,
      "start_date": "2020-08-31",
      "completion_date": "2022-11-16",
      "has_results": false,
      "last_update_posted_date": "2024-07-16",
      "last_synced_at": "2026-09-14T11:21:10.135Z",
      "location_count": 1,
      "location_summary": "Abingdon, Virginia",
      "locations": [
        {
          "city": "Abingdon",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04461587"
    },
    {
      "nct_id": "NCT04639310",
      "title": "XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy",
        "Epilepsy in Children",
        "Epilepsy; Seizure",
        "Disease",
        "Brain Diseases",
        "Central Nervous System Diseases",
        "Nervous System Diseases",
        "Epileptic Syndromes"
      ],
      "interventions": [
        {
          "name": "XEN496",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xenon Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "1 Month to 6 Years"
      },
      "enrollment_count": 8,
      "start_date": "2021-03-29",
      "completion_date": "2023-05-16",
      "has_results": true,
      "last_update_posted_date": "2024-08-23",
      "last_synced_at": "2026-09-14T11:21:10.135Z",
      "location_count": 11,
      "location_summary": "Orange, California • San Francisco, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04639310"
    },
    {
      "nct_id": "NCT00529438",
      "title": "RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Lymphoid Malignancies"
      ],
      "interventions": [
        {
          "name": "Bardoxolone methyl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2006-04-30",
      "completion_date": "2008-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-09-14T11:21:10.135Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Cleveland, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00529438"
    },
    {
      "nct_id": "NCT03894540",
      "title": "Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "IPN60090",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "IPN60090 single administration",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2019-03-22",
      "completion_date": "2020-12-21",
      "has_results": true,
      "last_update_posted_date": "2022-09-13",
      "last_synced_at": "2026-09-14T11:21:10.135Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03894540"
    },
    {
      "nct_id": "NCT00486512",
      "title": "Chemoprevention of Colorectal Adenomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adenomatous Polyps"
      ],
      "interventions": [
        {
          "name": "0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)",
          "type": "DRUG"
        },
        {
          "name": "75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)",
          "type": "DRUG"
        },
        {
          "name": "placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)",
          "type": "DRUG"
        },
        {
          "name": "placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)",
          "type": "DRUG"
        },
        {
          "name": "Colonoscopy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Colotech A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 350,
      "start_date": "2007-06",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2020-09-03",
      "last_synced_at": "2026-09-14T11:21:10.135Z",
      "location_count": 24,
      "location_summary": "Huntsville, Alabama • San Diego, California • Clearwater, Florida + 20 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00486512"
    }
  ]
}